Gefitinib for refractory advanced non-small-cell lung cancer [5]

Lancet

Volumn 367, Issue 9507, 2006, Pages 299-300

  Moriguchi, Hisashi ^a   Kim, Tae You ^b   Sato, Chifumi ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b Seoul National University Hospital   (South Korea)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GEFITINIB; OXIDOREDUCTASE;

CANCER SURVIVAL; DEMOGRAPHY; GENE MUTATION; HAZARD ASSESSMENT; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING;

EID: 31444440954     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68063-X     Document Type: Letter

References (5)

1. N Thatcher, A Chang, P Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
2. SW Han, TY Kim, PG Hwang Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2005 2493 2501
3. XT Zhang, LY Li, XL Mu The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer Ann Oncol 16 2005 1334 1342
4. TY Chou, CH Chiu, LH Li Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer Clin Cancer Res 11 2005 3750 3757
5. S Fukumoto, N Yamauchi, H Moriguchi Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas Clin Cancer Res 11 2005 1776 1785